{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:08:43Z","timestamp":1759565323985},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T00:00:00Z","timestamp":1439942400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00192-015-2809-3","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T01:39:29Z","timestamp":1439861969000},"page":"427-431","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?"],"prefix":"10.1007","volume":"27","author":[{"given":"Maya","family":"Basu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aswini","family":"Balachandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Duckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,19]]},"reference":[{"key":"2809_CR1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.108.142562","volume":"328","author":"M Wuest","year":"2009","unstructured":"Wuest M, Eichhorn B, Grimm M, Wirth M, Ravens U, Kaumann A (2009) Catecholamines relax detrusor through beta-2 adrenoreceptors in mouse and beta-3 adrenoreceptors in man. J Pharmacol Exp Ther 328:213\u2013222","journal-title":"J Pharmacol Exp Ther"},{"key":"2809_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.01.061","volume":"657","author":"M Michel","year":"2011","unstructured":"Michel M, Cernecka H, Ochodnicky P (2011) Desirable properties of \u03b23-adrenoreceptor agonists: implications for the selection of drug development candidates. Eur J Pharmacol 657:1\u20133","journal-title":"Eur J Pharmacol"},{"key":"2809_CR3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","volume":"321","author":"T Takasu","year":"2007","unstructured":"Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O (2007) Effect of ( R )-2-(2-aminothiazol-4-yl)-4\u2019-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), a novel selective beta-3-adrenoreceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642\u2013647","journal-title":"J Pharmacol Exp Ther"},{"key":"2809_CR4","doi-asserted-by":"crossref","first-page":"744.e1-7","DOI":"10.1016\/j.urology.2011.08.080","volume":"79","author":"S Kanie","year":"2012","unstructured":"Kanie S, Otsuka A, Yoshikawa S, Morimoto T, Hareyama N, Okazaki S, Kobayashi R, Hasebe K, Nakao K, Hayashi R, Mochizuki H, Matsumoto R, Ozono S (2012) Pharmacological effect of TRK-380, a novel selective human \u03b23-adrenoceptor agonist, on mammalian detrusor strips. Urology 79:744.e1-7","journal-title":"Urology"},{"key":"2809_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2014.06.052","volume":"67","author":"C Chapple","year":"2015","unstructured":"Chapple C, Khullar V, Nitti VW et al (2015) Efficacy of the \u03b23-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials. Eur Urol 67:11\u201314","journal-title":"Eur Urol"},{"key":"2809_CR6","author":"HC Kuo","year":"2014","unstructured":"Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K (2014) Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. doi: 10.1002\/nau.22645","journal-title":"Neurourol Urodyn"},{"key":"2809_CR7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","volume":"67","author":"P Abrams","year":"2015","unstructured":"Abrams P, Kelleher C, Staskin D et al (2015) Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). Eur Urol 67:577\u2013588","journal-title":"Eur Urol"},{"key":"2809_CR8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1464-410X.2003.04351.x","volume":"92","author":"J Malone-Lee","year":"2003","unstructured":"Malone-Lee J, Henshaw D, Cummings K (2003) Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int 92:415\u2013417","journal-title":"BJU Int"},{"key":"2809_CR9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1464-410X.2009.08361.x","volume":"103","author":"J Malone-Lee","year":"2009","unstructured":"Malone-Lee J, Al-Buheissi S (2009) Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 103:931\u2013937","journal-title":"BJU Int"},{"key":"2809_CR10","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1464-410X.2009.09037.x","volume":"105","author":"V Nitti","year":"2010","unstructured":"Nitti V, Rovner E, Bavendam T (2010) Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the finding of detrusor overactivity. BJU Int 105:1268\u20131275","journal-title":"BJU Int"},{"key":"2809_CR11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2012.11.060","volume":"699","author":"J Sval\u00f8","year":"2013","unstructured":"Sval\u00f8 J, Nordling J, Bouchelouche K, Andersson KE, Korstanje C, Bouchelouche P (2013) The novel \u03b23-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol 699:101\u2013105","journal-title":"Eur J Pharmacol"},{"key":"2809_CR12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/nau.20826","volume":"29","author":"N Aizawa","year":"2010","unstructured":"Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ (2010) Effects of CL316,243, a beta-3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 29:771\u2013776","journal-title":"Neurourol Urodyn"},{"key":"2809_CR13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","volume":"62","author":"N Aizawa","year":"2012","unstructured":"Aizawa N, Homma Y, Igawa Y (2012) Effects of mirabegron, a novel \u03b23-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol 62:1165\u20131173","journal-title":"Eur Urol"},{"key":"2809_CR14","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.1523\/JNEUROSCI.22-18-08063.2002","volume":"22","author":"L Birder","year":"2002","unstructured":"Birder L, Nealen M, Kiss S et al (2002) Beta-adrenoreceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci 22:8063\u20138070","journal-title":"J Neurosci"},{"issue":"5","key":"2809_CR15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/nau.21102","volume":"30","author":"A Kanai","year":"2011","unstructured":"Kanai A, Wyndaele J, Andersson K et al (2011) Researching bladder afferents- determining the effects of (3) adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn 30(5):684\u2013691","journal-title":"Neurourol Urodyn"},{"key":"2809_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0302-2838(02)00540-7","volume":"43","author":"KE Andersson","year":"2003","unstructured":"Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor--which is the main mechanism of action? Eur Urol 43:1\u20135","journal-title":"Eur Urol"},{"key":"2809_CR17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/nau.20826","volume":"229","author":"N Aizawa","year":"2010","unstructured":"Aizawa N, Igawa Y, Nishizawa O, Wyndaele J (2010) Effects of CL316,243, a beta-3-adrenoreceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 229:771\u2013776","journal-title":"Neurourol Urodyn"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-015-2809-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00192-015-2809-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-015-2809-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T08:17:36Z","timestamp":1599466656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00192-015-2809-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,19]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["2809"],"URL":"https:\/\/doi.org\/10.1007\/s00192-015-2809-3","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,19]]}}}